Leaving the lysosome behind: novel developments in autophagy inhibition.
Leaving the lysosome behind: novel developments in autophagy inhibition.
复制标题
将溶酶体留在后面：自噬抑制的新发展。
DOI：
10.4155/fmc.15.166
复制
发表时间：
2016-01
影响因子：
4.2
通讯作者：
MacKeigan JP
中科院分区：
文献类型：
--
作者：
Solitro AR;MacKeigan JP
寻找治疗癌症的灵丹妙药现在已经被针对每种恶性肿瘤甚至每个患者的独特的多种治疗靶点的确定所掩盖。近年来，自噬已成为这样一种治疗靶点。在对治疗性和致癌性应激的反应中，癌细胞上调并表现出对这种细胞内循环过程的依赖性。特别是在目前缺乏靶向治疗选择的恶性肿瘤中，自噬抑制剂是治疗这种疾病的下一个有希望的前景。在这篇综述中，我们讨论了自噬抑制剂从早期溶酶体抑制剂到下一代溶酶体靶向药物的快速演变。
The search for a single silver bullet for the treatment of cancer has now been overshadowed by the identification of multiple therapeutic targets unique to each malignancy and even to each patient. In recent years, autophagy has emerged as one such therapeutic target. In response to both therapeutic and oncogenic stress, cancer cells upregulate and demonstrate an increased dependence upon this intracellular recycling process. Particularly in malignancies that currently lack targeted therapeutic options, autophagy inhibitors are the next hopeful prospects for the treatment of this disease. In this review, we discuss the rapid evolution of autophagy inhibitors from early lysosomotropic agents to next-generation lysosome-targeted drugs and beyond.